Table A2.

Associations Between ER-α36 Expression and Clinicopathologic Characteristics in the Second Cohort of 186 Patients Who Only Received Tamoxifen

Characteristic	No. of Patients	ER-α36 Expression				P*
		Positive		Negative
		No.	%	No.	%
Total	186	86	46	100	54
Menopausal status						.62
Pre	53	23	27	30	30
Post	133	63	73	70	70
Tumor size, cm						.65
≤ 2	120	54	63	66	66
> 2	66	32	37	34	34
Lymph node status						.039
0	147	64	75	83	83
1-3	20	8	9	12	12
≥ 4	19	14	16	5	5
ER-α66 status						.90
Positive	156	73	85	83	86
Negative	27	13	15	14	14
Unknown	3			3
PgR status						.61
Positive	124	57	66	67	70
Negative	58	29	34	29	30
Unknown	4			4
HER-2 status						.40
Positive	36	19	22	17	17
Negative	149	67	80	82	83
Unknown	1			1
Histologic grade						.60
1	64	29	36	35	40
2	99	48	59	51	58
3	6	4	5	2	2
Unknown	17	5		12

Abbreviations: ER-α36, estrogen receptor-α 36; ER-α66, estrogen receptor-α 66; PgR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.

^*P values were derived from χ² test.